Selection of single chain human monoclonal antibody (scFv) against Rabies virus by phage display technology

Pruksametanan, Natcha; Yamabhai, Montarop; Khawplod, Pakamatz

doi:10.1109/nanomed.2012.6509127

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody library in this study was created from a healthy population that had previously encountered a myriad of antigens in the region of northeastern Thailand around 15 years ago, apparently from this study, including nitrogen-fixing soil bacteria. Specific scFv antibodies from this library has been generated against a wide variety of targets such as mycotoxins ( 15 , 25 ), venom ( 28 ), pathogenic bacteria ( 17 ), as well as virus ( 29 ) and cancer biomarker ( 30 ). From our previous study, the recombinant scFv antibody that could bind specifically to Bradyrhizobium strain DOA9 was successfully generated ( 18 ), from a phage-displayed rabbit scFv antibody library, created from an immunized rabbit.…”

Section: Discussionmentioning

confidence: 99%

Application of Recombinant Human scFv Antibody as a Powerful Tool to Monitor Nitrogen Fixing Biofertilizer in Rice and Legume

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Application of Recombinant Human scFv Antibody as a Powerful Tool to Monitor Nitrogen Fixing Biofertilizer in Rice and Legume

et al. 2021

View full text Add to dashboard Cite

show abstract

Nanotechnology for Therapy of Zoonotic Diseases: A Comprehensive Overview

et al. 2022

View full text Add to dashboard Cite

Zoonotic infections belong to multiple infectious diseases transferred from animals to humans. Now, the treatment and diagnosis of zoonotic infections are perplexing due to genetic mutations, target site modifications, and multi‐drug resistance. Despite their benefits, most diagnostic molecular techniques have certain limits in terms of repeatability and sensitivity, mainly due to the heterogeneity among the diverse family of zoonotic pathogens. Therefore, developing more efficient and cost‐effective theranostics tools is the need of the hour to address these concerns. For this purpose, nanotechnology has revolutionized medicine with versatile potential capabilities for diagnosing and treating zoonosis via the targeted and controlled delivery of antimicrobial drugs via binding to the overexpressed infectious macrophages. Massive advancements have been made in fabricating novel nano‐based formulations to control zoonosis based on the use of poly(ethylenimine)‐conjugated nanomicelles, mannosylated thiolated chitosan (MTC)‐coated PM‐loaded PLGA NPs, mannose linked thiolated nanocarriers, adjuvanted pDNA hydrogel, arginine‐based nanocarriers, quantum dots to treat and diagnose a wide range of zoonotic diseases, including zoonotic influenza, salmonellosis, leishmaniasis, rabies, brucellosis, Lyme Disease, tuberculosis, and other infections caused by West Nile Virus, emerging coronaviruses (SARS, MERS, COVID‐19), in a preferentially targeted way. Recently developed anti‐pathogen loaded‐nanoformulations with enhanced cellular uptake, biocompatibility, and hemocompatibility have shown the ability to cross biological barriers when orally administrated. Therefore, this article reviewed the latest milestones and future growth areas in the field of efficient theranostics platforms to manage zoonotic infections.

show abstract

Production and applications of fluorobody from redox-engineered Escherichia coli

Srila

Min

Sumphanapai

et al. 2023

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

Efficient selection and production of antibody fragments in microbial systems remain to be a challenging process. To optimize microbial production of single-chain variable fragments (scFvs), we have chosen five model targets, 1) a hapten, Zearalenone (ZEN) mycotoxin, along with infectious agents 2) rabies virus, 3) Propionibacterium acnes, 4) Pseudomonas aeruginosa, and a cancer cell 5) acute myeloid leukemia cell line (HL-60). The scFv binders were affinity selected from a non-immunized human phage display scFv antibody library and genetically fused to the N-terminus of emerald green fluorescent protein (EmGFP). The scFv-EmGFP fusion constructs were subcloned into an expression vector, under the control of T7 promoter, C-terminally tagged with hexa-histidine and expressed in different Escherichia coli (E. coli) hosts. This enabled the detection of cells that expressed the correct scFv-EmGFP fusion, termed fluorobody, via bright fluorescent signal in the cytoplasm. Among the three E. coli hosts tested, an engineered E. coli B strain called SHuffle B that promotes disulfide bond formation in the cytoplasm appeared to be the most appropriate host. The recombinant fluorobodies were well expressed (2–8 mg/L), possessed the fluorescence property of EmGFP, and retained the ability to bind to their cognate targets. Their specific bindings were demonstrated by ELISA, fluorescence-linked immunosorbent assay (FLISA), flow cytometry, and fluorescent microscope imaging. The fluorobody expression platform in this study could be further adopted as a one-step immunostaining technique based on scFv, isolated from phage display library to numerous desired targets. Key points • E. coli SHuffle express T7 is a suitable expression host for scFv-EmGFP (fluorobody) • Only the clones harboring scFv-EmGFP plasmid will show bright fluorescent signal • This platform can be used to produce fluorobodies for numerous purposes Graphical abstract

show abstract

Selection of single chain human monoclonal antibody (scFv) against Rabies virus by phage display technology

Cited by 3 publications

References 8 publications

Application of Recombinant Human scFv Antibody as a Powerful Tool to Monitor Nitrogen Fixing Biofertilizer in Rice and Legume

Application of Recombinant Human scFv Antibody as a Powerful Tool to Monitor Nitrogen Fixing Biofertilizer in Rice and Legume

Nanotechnology for Therapy of Zoonotic Diseases: A Comprehensive Overview

Production and applications of fluorobody from redox-engineered Escherichia coli

Contact Info

Product

Resources

About